<DOC>
	<DOCNO>NCT00004890</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill kidney cancer cell . Biomed 101 may protect normal cell side effect interleukin-2 . PURPOSE : Phase I trial study effectiveness Biomed 101 treat patient receive interleukin-2 kidney cancer .</brief_summary>
	<brief_title>Biomed 101 Interleukin-2 Treating Patients With Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety maximum tolerate dose Biomed 101 patient renal cell cancer currently treat interleukin-2 ( IL-2 ) . II . Evaluate effect different dos Biomed 101 incidence severity IL-2 related toxicity incidence frequency IL-2 dose reduction due IL-2 induced toxicity . OUTLINE : This dose escalation study Biomed 101 . Patients receive oral Biomed 101 three time daily , follow interleukin-2 IV day 1-5 16-20 . Cohorts 5 patient receive escalate dos Biomed 101 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 5 patient experience dose limit toxicity . Patients follow 1 month . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell cancer No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : WBC least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : No hepatic failure No encephalopathy Bilirubin great 2.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal : No renal dysfunction require dialysis great 72 hour Creatinine great 2.0 mg/dL Cardiovascular : No history sustain ventricular tachycardia ( great 5 beat ) No uncontrolled cardiac rhythm disturbances No recurrent chest pain echocardiogram change No angina No myocardial infarction No pericardial tamponade No moderate severe coronary artery disease ( New York Heart Association class 3 4 ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant neurological dysfunction include seizure clinical sign significant neurological disease No gastrointestinal bleed require surgery No concurrent infection require antimicrobial therapy No bowel ischemia perforation PRIOR CONCURRENT THERAPY : At least 30 day since prior investigational drug No concurrent investigational drug No intubation require great 72 hour No prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>drug extravasation</keyword>
</DOC>